Cartesian Therapeutics (RNAC) Change in Acquisitions & Divestments (2016 - 2023)

Cartesian Therapeutics (RNAC) has 7 years of Change in Acquisitions & Divestments data on file, last reported at $28.3 million in Q1 2023.

• Change in Acquisitions & Divestments for Q1 2023 came in at $28.3 million, up 182.54% year-over-year; the trailing twelve-month figure through Dec 2023 was $28.3 million (up 43.42% YoY), and the FY2023 annual result was $28.3 million, up 43.42% from the prior year.
• Change in Acquisitions & Divestments rose to $28.3 million in Q1 2023 per RNAC's latest filing, from $5.7 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $28.3 million in Q1 2023 and troughed at $2.0 million in Q1 2019.
• A 4-year average of $10.1 million and a median of $8.2 million in 2021 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2019 and 2023: Change in Acquisitions & Divestments slumped 86.76% in 2019, then surged 182.54% in 2023.
• A 4-year view of Change in Acquisitions & Divestments shows it stood at $14.4 million in 2019, then plunged by 30.35% to $10.0 million in 2021, then slumped by 43.0% to $5.7 million in 2022, then soared by 395.68% to $28.3 million in 2023.
• Business Quant data shows RNAC's Change in Acquisitions & Divestments at $28.3 million in Q1 2023, $5.7 million in Q4 2022, and $4.0 million in Q3 2022.